Compare Moderna, Inc. (MRNA) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs VICI Properties Inc — how do they compare? Moderna, Inc. trades at $135.84 (market cap $56.02B), while VICI Properties Inc trades at $25.32 (market cap $27.82B). The key difference: Moderna, Inc. is far larger — about 2× VICI Properties Inc's market cap, and VICI Properties Inc pays a 7.28% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | VICI | |
|---|---|---|
Market Cap | $56.02B | $27.82B |
Sector | Health | Real Estate |
52-Week High | $174.38 | $33.16 |
52-Week Low | $22.36 | $25.23 |
Enterprise Value | $52.17B | $45.38B |
Dividend Yield | — | 7.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
VICI trades at $25.29, down 0.51% today, with a bearish technical signal from moving averages but oversold RSI readings. The stock offers a high dividend yield above 7%, supported by strong profitability margins (net income margin 67.5% in 2025) and a low P/E of 9.79. Recent corporate actions include a dividend increase to $0.46 per share and the appointment of a new independent director, reflecting steady governance.
Outlook remains positive with a consensus price target of $29.29 (16% upside), driven by stable cash flows and REIT income appeal. Risks include earnings volatility (two recent EPS misses) and acquisition yield pressures. Institutional sentiment is bullish (77% buy ratings), but technical weakness near support at $25 requires monitoring for entry opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
